The LAT1 Transporter in Cancer, Health, and Disease

LAT1, formally known as SLC7A5, is an amino acid transporter embedded in cell membranes that ferries large, bulky amino acids into cells in exchange for others leaving. In healthy tissue, it performs essential gatekeeping duties at the blood-brain barrier, in the placenta, and in activated immune cells. In cancer, it becomes something closer to a supply line: tumor cells dramatically ramp up LAT1 expression to feed their accelerated growth, and high levels of the transporter predict worse survival outcomes across a range of solid tumors. That dual identity makes LAT1 both a window into how cancer rewires normal biology and an increasingly attractive target for diagnosis and treatment.

What LAT1 Actually Does

LAT1 is an exchanger, not a one-way pump. It swaps one amino acid inside the cell for another one outside, operating without any need for sodium or other ion gradients to power the trade. Its preferred cargo includes large neutral amino acids like leucine, phenylalanine, tyrosine, and tryptophan. When researchers loaded cells with leucine or glutamine and then offered substrates on the outside, those intracellular amino acids were pushed out in exchange, confirming the obligatory swap mechanism.¹ Beyond amino acids, LAT1 also handles thyroid hormones and a number of prescription drugs, making it relevant well beyond basic nutrition.²

LAT1 does not work alone. It forms a mandatory partnership with a larger glycoprotein called CD98hc (also known as 4F2hc). The two are locked together by a disulfide bond, and without CD98hc, LAT1 cannot reach the cell surface or function properly. High-resolution imaging of the complex revealed that LAT1 adopts a structural fold common to other transporters in the same superfamily but features an unusual loop on one of its membrane-spanning segments, creating an extended internal cavity large enough to accommodate the bulky amino acids and drugs it carries.³ CD98hc stabilizes LAT1 through contacts in the membrane, in the space outside the cell, and through interactions mediated by cholesterol. The dependence on this partner protein is so tight that genetic disruption of either CD98hc or LAT1 produces similar downstream effects in cells.

Normal Roles in the Body

In healthy adults, LAT1 expression is not widespread. It concentrates in a handful of tissues where controlled amino acid delivery is especially critical. The blood-brain barrier is the most studied site. Brain capillary endothelial cells rely on LAT1 to regulate which amino acids cross from the bloodstream into brain tissue, directly influencing neurotransmitter synthesis and overall brain metabolism.⁴ Because the brain cannot manufacture its own essential amino acids, this transporter is the primary gatekeeper for raw materials needed to produce serotonin (from tryptophan), dopamine (from tyrosine), and many proteins.⁵

The placenta is another site of high LAT1 activity. Both LAT1 and its close relative LAT2 are expressed in the outermost layer of placental cells that faces the maternal blood supply, where they help shuttle essential amino acids from mother to fetus. LAT2 shows up on the fetal side of the placenta too, suggesting the two isoforms work in tandem to move amino acids across the entire placental barrier.⁶

LAT1 also plays a specific role in immune activation. When T cells encounter an antigen and switch on, they need a sudden influx of essential amino acids to fuel the burst of protein production and cell division that follows. LAT1 expression ramps up sharply in activated human T cells. Blocking LAT1 with inhibitors or silencing its gene triggers an amino acid starvation response that suppresses the signaling cascades T cells depend on to produce inflammatory molecules.⁷ In mouse models of arthritis, deleting LAT1 specifically in helper T cells blocked the development of joint inflammation and prevented those T cells from producing key inflammatory signals, without disturbing regulatory T cells that keep the immune system in check.⁸ That selectivity for inflammatory over regulatory T cells has prompted interest in LAT1 as a potential therapeutic target for autoimmune diseases like rheumatoid arthritis.

LAT1 and Skeletal Muscle

Leucine is one of the most potent dietary signals for triggering muscle protein synthesis, and LAT1 is the primary transporter responsible for moving leucine into muscle fibers. Resistance training increases LAT1 protein content in human skeletal muscle over a period of weeks.⁹ More of the transporter appeared in the total fiber after training, though the amount specifically at the cell membrane did not change as clearly. In lab-grown muscle cells, blocking LAT1 with drugs or genetic knockdown impaired the ability of precursor cells to survive, differentiate into mature muscle fibers, and fuse together, indicating that amino acid transport through LAT1 is required for normal muscle development.¹⁰ For anyone interested in exercise physiology, LAT1 sits at the intersection of dietary amino acid sensing and the anabolic response to training.

How Cancer Hijacks LAT1

Tumor cells grow fast, and that growth demands a constant stream of building blocks. LAT1 is overexpressed in a wide range of cancers, including lung, pancreatic, breast, renal, and biliary tract tumors, giving malignant cells a competitive advantage in grabbing amino acids from the surrounding tissue. Once inside the cell, leucine and other branched-chain amino acids delivered by LAT1 activate the mTORC1 signaling pathway, a master regulator of protein synthesis and cell growth.¹¹

When researchers genetically knocked out LAT1 in colon cancer cells, amino acid import collapsed and cells activated a stress-response pathway called GCN2 at roughly ten times the normal level. At the same time, mTORC1 activity, measured by the phosphorylation of a downstream marker, dropped by about half under conditions mimicking the nutrient levels tumors actually face in the body.¹² In short, without LAT1, cancer cells starve themselves of the amino acids needed to keep their growth machinery running.

Several forces drive LAT1 overexpression in tumors. The oncogene c-Myc, one of the most commonly activated cancer-promoting genes, directly boosts LAT1 production. In pancreatic cancer cells, silencing c-Myc caused a severe drop in both LAT1 protein and its messenger RNA, and the LAT1 gene promoter contains a binding site for c-Myc that, when mutated, eliminates the effect.¹³ Hypoxia, the low-oxygen environment found deep inside solid tumors, also pushes LAT1 expression upward through a separate set of transcription factors called hypoxia-inducible factors (HIFs).¹⁴ So both genetic mutations and the physical microenvironment of a tumor converge on keeping LAT1 levels high.

LAT1 as a Prognostic Marker

A systematic review and meta-analysis pooling data from studies of patients with solid tumors found that high LAT1 expression was consistently associated with worse outcomes. The pooled hazard ratios indicated that patients with elevated LAT1 had roughly 85 percent higher risk of death and about 90 percent higher risk of disease recurrence compared to those with low expression.¹⁵ The pattern held across cancer types, with particularly strong associations in non-small cell lung cancer, pancreatic cancer, and biliary tract cancer. In renal cell carcinoma, where about 92 percent of tumor specimens showed LAT1 expression, higher levels predicted shorter overall survival and faster disease progression.¹⁵ These findings suggest that measuring LAT1 expression in biopsied tissue could help clinicians gauge how aggressive a tumor is likely to be.

PET Imaging That Targets LAT1

One of the most clinically advanced applications of LAT1 biology is in medical imaging. PET scans that use radiolabeled amino acids designed to enter cells through LAT1 can light up tumors with high specificity. The advantage over conventional glucose-based PET scans is that amino acid tracers produce much less background noise in normal tissue, because most healthy cells outside the brain express little LAT1. This means sharper tumor boundaries and fewer false positives from inflammation, which glucose-based tracers often cannot distinguish from cancer.¹⁶

Established LAT1-targeting PET tracers include compounds labeled with fluorine-18, and newer candidates continue to emerge. One recently developed methylated phenylalanine tracer showed better uptake in brain tumors in mice and clearer boundary definition than the clinically used tracer FET.¹⁷ Another useful property of these tracers: their distribution in tumors reflects the amount of functional LAT1 present rather than the rate of blood flow to the tumor, making the signal a more direct readout of transporter activity.¹⁸ For brain tumors in particular, where glucose-based PET is hampered by the brain’s naturally high glucose consumption, amino acid PET tracers targeting LAT1 offer a genuinely useful alternative.

Boron Neutron Capture Therapy

Boron neutron capture therapy (BNCT) is a radiation treatment that works by loading tumor cells with a boron-containing compound and then bombarding the area with a beam of slow neutrons. When the neutrons hit boron atoms, a nuclear reaction produces short-range particles that destroy the cell from within while sparing its neighbors. The selectivity of BNCT depends entirely on getting enough boron into cancer cells but not normal ones, and the boron carrier used most often, boronophenylalanine (BPA), enters cells through amino acid transporters. LAT1 transports BPA with high affinity, and the amount of LAT1 protein in a cancer cell line is the strongest predictor of how much BPA it will take up.¹⁹

Because aggressive tumors like gliomas and certain subtypes of lung and breast cancer frequently overexpress LAT1, they naturally accumulate more BPA than the surrounding normal tissue, which is exactly what makes BNCT tumor-selective in those settings.²⁰ The main challenge is that not all tumors express LAT1 uniformly, so boron delivery can be uneven. Researchers are working on strategies to boost LAT1-mediated BPA uptake, including combination approaches and next-generation boron compounds designed to exploit the transporter more efficiently.

Inhibiting LAT1 as a Cancer Treatment

If tumors depend on LAT1 to feed their growth, then blocking the transporter should starve them. Several drug candidates built on this logic are in development. The most studied is JPH203, which at low concentrations sensitized cancer cells to radiation by driving them into a state of irreversible growth arrest. The mechanism appears to involve shutting down mTOR signaling when the amino acid supply dries up.²¹ This combination strategy, pairing a LAT1 inhibitor with conventional radiotherapy, could lower the radiation doses needed while improving effectiveness.

A newer approach, described as “locking inhibition,” goes beyond simply competing with amino acids for LAT1’s binding site. In animal models, a compound using this mechanism achieved more than 70 percent tumor growth suppression in xenograft models without causing weight loss or systemic toxicity, and safety testing in rodents and dogs confirmed a favorable profile with no off-target effects.²² A separate inhibitor, KMH-233, was shown to induce cancer cell death at concentrations that did not affect blood coagulation or alter amino acid levels in the brains of mice, addressing one of the major safety concerns about targeting a transporter so important at the blood-brain barrier.²³

That safety concern is not trivial. LAT1 controls amino acid supply to the brain, so a systemically administered inhibitor that blocked LAT1 everywhere could theoretically impair brain function. The fact that KMH-233 did not change brain levels of leucine, tyrosine, or tryptophan at effective anti-cancer doses suggests that the therapeutic window may be wider than feared, possibly because the drug’s pharmacokinetics limit its exposure at the blood-brain barrier or because other transporters partially compensate in the brain.

Using LAT1 to Deliver Drugs Into the Brain

Rather than blocking LAT1, an entirely different therapeutic strategy exploits it as a delivery route. The blood-brain barrier keeps most drugs out of the brain, which is a major obstacle for treating neurological diseases. Because LAT1 is one of the few active transport systems on the barrier, researchers have designed prodrugs, inactive drug precursors shaped to look like LAT1’s natural amino acid cargo, that hitch a ride across the barrier and then release the active drug once inside the brain.²⁴

One example involved prodrugs of valproic acid, an anti-epileptic drug. By attaching the drug to a modified phenylalanine backbone designed to bind LAT1, researchers found that all the resulting prodrugs crossed the blood-brain barrier in rat experiments. A novel structural tweak, placing the attachment point at a different position on the phenylalanine ring, improved LAT1 binding affinity tenfold and doubled the amount of drug reaching the brain compared to earlier designs.²⁵ LAT1 is expressed at comparable levels in neurons, brain support cells called astrocytes, and immune cells of the brain called microglia, meaning that prodrugs entering through LAT1 can potentially reach all three cell types once across the barrier.²⁶

This approach is not limited to small-molecule drugs. Gold nanoparticles coated with L-DOPA, a LAT1 substrate, accumulated far more readily in breast cancer cells than uncoated particles, while showing no increased uptake in non-cancerous breast cells. The nanoparticles were designed for photothermal therapy, where near-infrared light heats the gold particles to kill cells they have accumulated in.²⁷ The tumor selectivity came from the fact that cancer cells overexpress LAT1 while normal cells do not, making the transporter a natural address label for targeted delivery.

LAT1 in Neurological Disease

Given LAT1’s role at the blood-brain barrier, it is not surprising that disruptions to the transporter have neurological consequences. Researchers identified patients carrying loss-of-function mutations in the SLC7A5 gene (the gene encoding LAT1) who showed autistic traits and motor delay.²⁸ Impaired amino acid transport into the developing brain during critical periods could plausibly affect neurotransmitter production and neuronal development, offering a mechanistic link between transporter dysfunction and neurodevelopmental conditions.

In a mouse model of Parkinson’s disease, LAT1 expression in brain capillaries dropped by about 63 percent within a week of the chemical insult that killed dopaminergic neurons. Expression in the brain as a whole fell by about 46 percent on the same timeline. No other transporter examined, including those for glucose, creatine, and monoamine neurotransmitters, showed a comparable decline.²⁹ This is particularly relevant because levodopa, the most widely used drug for Parkinson’s, crosses the blood-brain barrier through LAT1. If the transporter is downregulated in Parkinson’s patients the way it is in the mouse model, it could mean that less levodopa reaches the brain over time, partly explaining why the drug becomes less effective as the disease progresses. It also means dietary amino acids, which compete with levodopa for the same transporter, could have a larger-than-expected effect on drug absorption. This is one reason neurologists often advise Parkinson’s patients to be mindful of protein intake around the time they take their medication.

LAT1 and Drug Resistance in Breast Cancer

An emerging line of research connects LAT1 to how breast cancers develop resistance to endocrine therapies like tamoxifen and fulvestrant. When researchers compared tamoxifen-sensitive and tamoxifen-resistant breast cancer cell lines, they found altered expression of over a hundred solute carrier genes, with LAT1 among those flagged by both RNA analysis and unbiased protein profiling as differentially expressed in resistant cells.³⁰ The hypothesis is that resistant cancer cells rewire their nutrient uptake machinery to sustain growth when hormone signaling is shut off by therapy, and LAT1’s ability to supply essential amino acids makes it a natural part of that metabolic workaround. This work is still at an early stage, but if LAT1 upregulation contributes to endocrine resistance, targeting the transporter alongside hormonal therapies could delay or overcome resistance in some patients.